Abbott Laboratories Hits New 52-Week Low at USD 104.11

Abbott Laboratories has reached a new 52-week low, trading at USD 104.11 on March 23, 2026. This marks a significant decline for the company, which operates within the Pharmaceuticals & Biotechnology sector and boasts a market capitalization of approximately USD 214.68 billion. Over the past year, Abbott's stock performance has seen a decrease of 2.46%, contrasting sharply with the S&P 500's gain of 16.12%. Despite this recent downturn, Abbott Laboratories maintains a strong financial position, characterized by a low debt-to-equity ratio of 0.10 and a robust ability to service its debt, evidenced by a debt-to-EBITDA ratio of 0.62 times. The company has demonstrated healthy long-term growth, with an operating profit growth rate of 13.45% annually. Additionally, Abbott has reported positive results for the last three consecutive quarters, highlighting its operational resilience. The stock's 52-week high stands at USD 139.06, indicating a notable gap from its current trading level. Investors may find interest in the company's attractive valuation metrics, including a return on capital employed (ROCE) of 13.01% and a PEG ratio of 0.1, suggesting potential for future growth.